
Feb 11 (Reuters) - SpringWorks Therapeutics Inc SWTX.O:
SPRINGWORKS THERAPEUTICS ANNOUNCES FDA APPROVAL OF GOMEKLI™ (MIRDAMETINIB) FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN
Source text: ID:nGNX2JBPk7
Further company coverage: SWTX.O